Familial Cancer

, Volume 11, Issue 3, pp 459–466

Microsatellite instability testing in Korean patients with colorectal cancer

Authors

  • Jung Ryul Oh
    • Department of SurgerySeoul National University Bundang Hospital
    • Department of SurgerySeoul National University Bundang Hospital
    • Korean Hereditary Tumor Registry, Cancer Research InstituteSeoul National University College of Medicine
  • Hye Seung Lee
    • Department of PathologySeoul National University Bundang Hospital
  • Hee Eun Lee
    • Department of PathologySeoul National University Bundang Hospital
  • Sung Min Lee
    • Department of SurgerySeoul National University Bundang Hospital
  • Je-Ho Jang
    • Department of SurgerySeoul National University Bundang Hospital
  • Sung-Bum Kang
    • Department of SurgerySeoul National University Bundang Hospital
  • Ja-Lok Ku
    • Korean Hereditary Tumor Registry, Cancer Research InstituteSeoul National University College of Medicine
  • Seung-Yong Jeong
    • Korean Hereditary Tumor Registry, Cancer Research InstituteSeoul National University College of Medicine
  • Jae-Gahb Park
    • Korean Hereditary Tumor Registry, Cancer Research InstituteSeoul National University College of Medicine
Original Article

DOI: 10.1007/s10689-012-9536-4

Cite this article as:
Oh, J.R., Kim, D., Lee, H.S. et al. Familial Cancer (2012) 11: 459. doi:10.1007/s10689-012-9536-4

Abstract

Microsatellite instability (MSI) testing is useful for identifying patients with hereditary nonpolyposis colorectal cancer and detecting sporadic colorectal cancer that develops through replication error pathways. A pentaplex panel is recommended by the National Cancer Institute for MSI testing, but simplified mononucleotide panels and immunohistochemistry of mismatch repair proteins are widely employed for convenience. This study was to evaluate the MSI status of colorectal cancer in Korean patients. This study included 1,435 patients with colorectal adenocarcinoma subjected to surgical resection. The pentaplex Bethesda panel was used for MSI testing. Seventy nine (5.5 %) carcinomas were classified as MSI-high (MSI-H) and 95 (6.6 %) as MSI-low (MSI-L). BAT-26 and BAT-25 were unstable in 73 and 75 of 79 MSI-H carcinomas, respectively. With the panel comprising these 2 mononucleotide markers, 72 carcinomas were diagnosed as MSI-H, compared to the Bethesda panel data (72/79, 91.1 %). In contrast, BAT-26 or BAT-25 were unstable in only 7 (7.4 %) of the 95 MSI-L tumors. In the panel with 2 dinucleotide markers, D17250 linked to p53 and D2S123 to hMSH2, detection rates were 89.9 % (71/79) for MSI-H and 80.0 % (76/95) for MSI-L carcinomas, compared to the Bethesda panel. Moreover, we compared the frequency of MSI tumor in our patients with those reported previously from Western countries. In conclusion, the frequency of MSI-H appears lower in colorectal cancer patients in Korea. A simplified panel for MSI testing with BAT-26 and BAT-25 seems not effective for the accurate evaluation of MSI status, particularly in MSI-L colorectal carcinomas, in our patients.

Keywords

Colorectal cancer Ethnic difference Hereditary nonpolyposis colorectal cancer, HNPCC Microsatellite instability, MSI

Copyright information

© Springer Science+Business Media B.V. 2012